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The Brazilian Journal of Infectious Diseases just received its second impact factor by Journal of 
Citation Report (JCR), which showed an expressive increment (45%) in comparison with the 
first one, obtained in 2010. We would like to share this good news with our editorial board, and 
thank all the referees that contributed to this great achievement. Our goals to the next years are 
to maintain an increasing level of quality of published papers, and a fast, efficient, and reliable 
editorial process. A special thank to the referees that have contributed to the revision of manu-
scripts submitted to BJID in the year of 2011 (see Appendix on page 621).
We are also glad to publish an extremely relevant reflection of Dr. Evaldo Stanislau Affonso 
de Araújo regarding hepatitis C therapy. Hepatitis C virus infection is already a major public 
health concern, and contributes to a significant number of deaths worldwide. Although the 
conventional therapy to treat such infection is only effective for a subset of patients, the devel-
opment of new drugs increased the chances of cure, even for patients failing previous therapy 
with pegylated interferon plus ribavirin. An impressive number of new drugs are being tested 
and promise to revolutionize the treatment of HCV infection in the near future. In this issue, 
Dr. Evaldo Stanislau Affonso de Araújo reviews the main aspects of the newly released HCV 
protease inhibitors, boceprevir and telaprevir, and comments the potential impact of these new 
drugs on HCV treatment, along with some reflections on its role in our future treatment strate-
gies of this important infection.
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